Table 1 Baseline clinical characteristics of the training and validation cohort
From: Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma
| Ā | Total (nā=ā151) | Training (nā=ā103) | Validation (nā=ā48) | P values |
|---|---|---|---|---|
Age(years), median (IQR) | 58.0 (51.0, 67.0) | 61.0 (50.3, 68.0) | 56.0 (51.0, 64.0) | 0.307 |
Gender, no.(%) | Ā | Ā | Ā | 0.355 |
Ā Male | 119 (78.8) | 79 (76.7) | 40 (83.3) | Ā |
Ā Female | 32 (21.2) | 24 (23.3) | 8(16.7) | Ā |
ALT, (U/L), median (IQR) | 33.5 (20.8, 47.8) | 29.70 (20.7, 45.3) | 35.4 (20.9, 52.9) | 0.220 |
AST, (U/L), median (IQR) | 33.0 (24.4, 44.1) | 32.4 (24.5, 43.4) | 33.9 (24.0, 49.8) | 0.407 |
GGT, (U/L), median (IQR) | 50.8 (29.2, 108.8) | 49.6 (30.2, 92.7) | 52.1 (27.9, 144.5) | 0.771 |
AFP, (Āµg/L), median(IQR) | 15.3 (3.1, 417.5) | 15.5 (3.1, 527.4) | 11.6 (2.9, 301.6) | 0.718 |
AFP group.no(%) | Ā | Ā | Ā | 0.555 |
Ā ā¤ā20Ā Āµg/L | 79 (52.3) | 54 (52.4) | 25 (52.1) | Ā |
Ā 20ā400Ā Āµg/L | 34 (22.5) | 21 (20.4) | 13 (27.1) | Ā |
Ā >ā400Ā Āµg/L | 38 (25.2) | 28 (27.2) | 10 (20.8) | Ā |
Hepatitis B, no.(%) | Ā | Ā | Ā | 0.856 |
Ā Negative | 36 (23.8) | 25 (24.3) | 11 (22.9) | Ā |
Ā Positive | 115 (76.2) | 78 (75.7) | 37 (77.1) | Ā |
Hepatitis C, no.(%) | Ā | Ā | Ā | 1.000 |
Ā Negative | 145 (96.0) | 99 (96.1) | 46 (95.8) | Ā |
Ā Positive | 6 (4.0) | 4 (3.9) | 2 (4.2) | Ā |
Cirrhosis, no.(%) | Ā | Ā | Ā | 0.520 |
Ā Negative | 43 (28.5) | 31 (30.1) | 12 (25.0) | Ā |
Ā Positive | 108 (71.5) | 72 (69.9) | 36 (75.0) | Ā |
Tumor grade, no.(%) | Ā | Ā | Ā | 0.398 |
Ā Low-grade tumor | 100 (66.2) | 71(68.9) | 29(60.4) | Ā |
Ā High-grade tumor | 51(33.8) | 32 (31.0) | 19(39.6) | Ā |